ReviewMayo Clinic proceedings2009
Beta-blocker use for the stages of heart failure.
Review in Mayo Clinic proceedings, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 78 citations in OpenAlex.
- Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction.Heart failure reviews · 2023Review
- Role of β-blockers in Preventing Heart Failure and Major Adverse Cardiac Events Post Myocardial Infarction.Current cardiology reviews · 2023Review
- Clostridium butyricum and Bifidobacterium pseudolongum Attenuate the Development of Cardiac Fibrosis in Mice.Microbiology spectrum · 2022Article
- Association Between Cholinesterase Inhibitors and New-Onset Heart Failure in Patients With Alzheimer's Disease: A Nationwide Propensity Score Matching Study.Frontiers in cardiovascular medicine · 2022Article
- Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives.Journal of geriatric cardiology : JGC · 2021Article
- Carvedilol and metoprolol are both able to preserve myocardial function in type 2 diabetes.Physiological reports · 2020Article
- Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies.Journal of clinical medicine · 2020Review
- Association of Arsenic Exposure With Cardiac Geometry and Left Ventricular Function in Young Adults.Circulation. Cardiovascular imaging · 2019Article
- Proarrhythmic Remodeling of Calcium Homeostasis in Cardiac Disease; Implications for Diabetes and Obesity.Frontiers in physiology · 2018Review
- Therapeutic Potential of Polyphenols in Cardiac Fibrosis.Frontiers in pharmacology · 2018Review
- Article
- Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease.Nature reviews. Drug discovery · 2016Review
- Review
- Review
- Systems analysis reveals down-regulation of a network of pro-survival miRNAs drives the apoptotic response in dilated cardiomyopathy.Molecular bioSystems · 2015Article
- PKA catalytic subunit compartmentation regulates contractile and hypertrophic responses to β-adrenergic signaling.Journal of molecular and cellular cardiology · 2014Article
- Aromatic Amines Exert Contrasting Effects on the Anticoagulant Effect of Acetaldehyde upon APTT.Advances in hematology · 2014Article
- Targeting GSK-3 family members in the heart: a very sharp double-edged sword.Journal of molecular and cellular cardiology · 2011Review
- Computational models reduce complexity and accelerate insight into cardiac signaling networks.Circulation research · 2011Review
- Bucindolol: a pharmacogenomic perspective on its use in chronic heart failure.Clinical Medicine Insights. Cardiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2005 American Heart Association/American College of Cardiology heart failure (HF) guidelines contributed to a renewed focus on "at-risk" patients and emphasized HF as a progressive disease. Patient categorization by stages focused attention on customization of therapy to achieve optimal, evidence-based treatments across the HF continuum. Therapy for risk factors that predispose patients to left ventricular dysfunction or other symptoms may help reduce HF development. beta-Blockers are valuable for treatment of HF; however, the class is heterogeneous, and proper beta-blocker selection for each HF stage is important. beta-Blockers have been used routinely to treat patients with stage A HF with hypertension. Recent controversy regarding the detrimental effects that some beta-blockers have on metabolic parameters has raised inappropriate concerns about the use of any beta-blocker for diabetes. beta-Blockade is standard therapy for the patient with stage B HF who has had a myocardial infarction, but few data are available concerning use in asymptomatic patients with left ventricular dysfunction. Additionally, beta-blockers are part of the core therapy for stage C HF and selected patients with stage D HF. This review examines the role and use of beta-blockers in each HF stage through an evidence-based approach to provide better understanding of their importance in this progressive disease. PubMed searches (1980-2008) identified large clinical trials that evaluated cardiovascular events and outcomes in any HF stage or hypertension. Search terms were heart failure, hypertension, beta-blocker, ACEI, ARB, and calcium channel blocker AND blood pressure coronary artery disease, diabetes, efficacy, left ventricular dysfunction, metabolism, mortality, myocardial infarction, or stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.